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Abstract
Background: Tissue engineering and bone substitutes are subjects of intensive ongoing research. If the healing of
bone fractures is delayed, osteoinductive materials that induce mesenchymal stem cells (MSCs) to form bone are
necessary. The use of Bone Morphogenetic Protein - 2 is a common means to enhance effectiveness and accelerate
the healing process. A delivery system that maintains and releases BMP biological activity in controlled fashion at
the surgical site while preventing systemic diffusion (and thereby the risk of undesirable effects by controlling the
amount of protein implanted) is essential.
In this study, we aimed to test a cylindrical TCP-scaffold (porosity ~ 40 %, mean pore size 5 μm, high
interconnectivity) in comparison to BMP-2. Recombinant human BMP-2 was dissolved in different hydrogels as a
carrier, namely gelatin and alginate cross-linked with CaCl2-solution, or a solution of GDL and CaCO3. FITC-labeled
Protein A was used as a model substance for rhBMP-2 in the pre-trials. For loading, the samples were put in a flow
chamber and sealed with silicone rings. Using a directional vacuum, the samples were loaded with the
alginate-BMP-2-mixture and the loading success monitored by observing changes in a fluorescent dye (FITC labeled
Protein A) under a fluorescence microscope. A fluorescence reader and ELISA were employed to measure the
release. Efficacy was determined in cell culture experiments (MG63 cells) via Live-Dead-Assay, FACS, WST-1-Assay,
pNPP alkaline phosphatase assay and confocal microscopy. For statistical analysis, we calculated the mean and
standard deviation and carried out an analysis of variance.
Results: Directional vacuum makes it possible to load nearly 100 % of the interconnected micropores with alginate
mixed with rhBMP-2. Using alginate hardened with CaCl2 as a carrier, BMP-2's release can be decelerated
significantly longer than with other hydrogels - eg, for over 28 days. The effects on osteoblast-like cells were an
increase of the growth rate and expression of alkaline phosphatase while triggering no toxic effect.
Conclusion: The rhBMP-2-loaded microporous TCP scaffolds possess proliferative and osteoinductive potential.
Alginate helps to lower the local growth factor dose below the cytotoxic limit, and allows the release period to be
lengthened by at least 28 days.
Keywords: β-Tricalciumphosphate, Porous ceramics, Biomaterials, Alginate, Delayed drug release, Bone
Morphogenetic Protein - 2 (BMP-2)
* Correspondence: steffen.kissling@t-online.de
Center for Surgery, Department of Orthopedics and Trauma Surgery, Medical
Center - University of Freiburg, Hugstetter Str.55, D-79106 Freiburg, Germany
© 2016 Kissling et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kissling et al. BMC Biotechnology  (2016) 16:44 
DOI 10.1186/s12896-016-0275-8
Background
The healing of bone fractures, especially critical size de-
fects, poses a great challenge in medicine. Autologous
bone grafts are routinely used, but they have drawbacks
such as limited quantity and accessibility [1] and donor
site morbidity. Alternative methods such as allografts,
xenografts, and synthetic materials [2] were thus devel-
oped to repair bone. For human application, they must
be non-toxic, non-carcinogenic, non-allergenic and non-
inflammatory, as well as biocompatible and biofunc-
tional. Many scaffolds made of synthetic materials have
evolved from a variety of materials like metal, polymers,
and ceramics.
Ceramics are defined as being inorganic, non-metallic
materials generally characterized by extreme hardness,
brittleness, low electrical and thermal conductivity, great
compressive strength and high chemical resistance, the
latter being demonstrated by their resistance to body
fluids. Epple classifies ceramic biomaterials in two cat-
egories: hard bio-inert ceramics such as zirconia or alu-
mina, and biodegradable ceramics [3]. The latter consist
of mostly calcium phosphates, which are used in bone
regeneration because of their similarity to inorganic
bone components such as hydroxyapatite (HA). Many
calcium phosphates are used in tissue engineering. Spe-
cial attention should be paid to the β-
Tricalciumphosphate (β-TCP) below. β-TCP has a
slightly different composition and thus another calcium/
phosphate ratio (HA 1.67; β-TCP 1.5) [4], resulting in
more than twice HA’s solubility in water and better de-
gradability than HA. In medicine, β-TCP is used alone
or mixed with HA (biphasic calcium phosphate) as a
bone substitute material [3]. For reasons of stability, the
ceramic should degrade while the new bone is forming.
β-TCP has proven to be a suitable material regarding its
biodegradability and mechanical stability [5].
From a structural perspective, macroporous (100–
1000 μm) scaffolds allow cell migration and boost angio-
genesis [6] and resorption from the inner surface of the
pores, while the microporosity within the scaffolds ex-
erts a positive influence on bone integration in calcium
phosphate scaffolds while resorption is taking place from
the outer surface. There is evidence that bone density
and its mass increase thereby, and that the scaffold’s
osteointegration improves [7]. Combined macro- and
microporous materials have recently demonstrated good
ingrowth [8].
Since TCP is brittle and its high porosity leads to weak
mechanical properties, our group postulated that >60 %
dense TCP materials (porosity <40 %) could be used as
scaffold for bone grafting and soft tissue fixation. We as-
sumed that micropores (5 μm) would reduce brittleness
by hindering crack propagation and preventing bone for-
mation on the joint surface, and that their high
interconnectivity would facilitate the nutrient transport
essential for tissue engineering.
This concept was tested with a cylindrical TCP-
scaffold (porosity nearly 40 %, mean pore size 5 μm, high
interconnectivity, axial failure load 7200 N/cm 2) in vitro
and vivo. The experiments included their use as fixation
for ligamentoplasties, as bone substitution [9], and as a
treatment for osteochondral defects in sheep [10, 11].
The implants displayed high mechanical stability
(equivalent to healthy bone) [12]. The TCP resorption
rate was 31 %, and 39 % of the resorbed TCP had been
replaced by mineralized bone 24 weeks after implant-
ation. Resorption took place almost exclusively on the
surface, as expected [9]. This TCP scaffold seeded with
chondrocytes is also suitable for treating osteochondral
defects [11].
The repair of non-critically-sized bone defects can be
achieved via osteoconductive TCP scaffolds. To repair
critically-sized bone defects, osteoinductive materials in-
ducing mesenchymal stem cells (MSCs) to form bone
are necessary. The use of growth factors is a common
means of enhancing effectiveness and accelerating the
healing process: BMP-2 is one that triggers increased
bone formation [13, 14]. What is essential is a delivery
system that maintains and releases BMP biological activ-
ity in controlled fashion at the surgical site while pre-
venting systemic diffusion (and thereby the risk of
undesirable effects by controlling the amount of protein
implanted). The combination of microporous calcium
phosphate scaffolds and BMP-2 can accelerate healing
up to 4-fold [15]. In view of these encouraging results,
we aimed to test this scaffold’s function with Bone Mor-
phogenetic Protein – 2 (BMP-2) in this study.
Two products using BMP-2 are commercially available
and have been approved (InductOS®, Pfizer; InFUSE®,
Medtronic) [16]. Both use collagen sponges and very
high doses of BMP-2 (12 mg) without a system for re-
tarded release. Clinically speaking, large doses of BMP-2
combined with a collagen matrix have triggered many
side effects such as swelling [17], hematomas, and ossifi-
cation at unintentional sites [18], and even a higher risk
of cancer [19]. High in-vitro doses of BMP-2 have toxic
effects on osteoblasts [20]. Another challenge when
using BMP-2 for bone repair is its very short half-life
lasting about 7 min [21]. We therefore need a delivery
system that can prevent the growth factor from degrad-
ing prematurely and enable the local dose to be lowered
while guaranteeing long-term delivery. Such a retarded
therapeutic application should minimize complications.
The delivery can be retarded by different methods.
You can bind substances adhesively or covalently to the
bone substitute [22], load micro- and nanoparticles with
agents [23], or use polymers like hydrogels or polylac-
tides as a carrier [24].
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The goal of this research was to achieve a pre-defined
release of BMP-2 lasting several weeks by coupling the
growth factor to a hydrogel and thus improve the
mechanically-stable scaffold for bone replacement with
enhanced osteoinductive properties.
Methods
The ceramic we chose to examine is β-TCP having a
total porosity of <40 %, while the interconnected micro-
pores have an average pore diameter of 5 μm. This was
used as cylindrically-shaped dowels 5 mm long and
7 mm in diameter, as described in previous studies [25].
Production and characterization of the ß-TCP dowels
To manufacture the ß-TCP dowels, a paste containing
80 g of α-tricalcium phosphate (α-TCP; Ca3(PO4)2) and
20 g of tricalcium phosphate (Merck, Switzerland) was
mixed for 2.5 min with 60.0 ± 0.2 g of a solution con-
taining 0.2 M Na2HPO4 and +1 % polyacrylic acid
(Fluka, Switzerland). During the hardening process
(45 min), the paste was poured into plastic syringes
whose tip had been cut off (Ø = 23 mm) and then cov-
ered with 10 ml of phosphate buffer saline pH 7.4 and
incubated for 3 days at 60 °C. After drying, the ceramics
were sintered at 1250 °C for 4 h, while heating and cool-
ing took place at 1 °C/min. The cylinders were then ma-
chined to obtain plugs of 25 mm long and 7 mm in
diameter and calcined at 900 °C to burn off all organic
residues. Afterwards the plugs were cut into 5 mm long
dowels and then washed in ethanol and distilled water in
an ultrasonic bath to remove residual wear particles and
sterilized by heat (200 °C, 4 h) for cell culture trials. This
fabrication process has been described in greater detail
in previous studies [5, 12, 25].
The fabricated ß-TCP plugs were phase pure as assessed
by X-ray diffraction (XRD) and tested on a Bruker axs D8
Advance X-ray diffractometer (Billerica, USA).
The ceramics were microporous (mean pore size 5.05
± 1.61 μm) with interconnecting pores and a total poros-
ity of 35.2 ± 1.5 %. Porosity was assessed on a POROTEC
Pascal 440 (Hofheim, Germany) mercury porosimeter.
FITC-Protein A as a model substance
In the pretrial, Protein A (441 AS, 42 kDa) was used as a
model substance for rhBMP-2 (396 AS, homodimer
30 kDa) because of its similar hydrodynamic volume and
chemical structure. Apart from the financial aspects,
Protein A can be FITC-labeled (Invitrogen, California),
making measuring easy and precise.
Hydrogels as carrier systems
We chose to evaluate three hydrogels: alginate 5 % w/v
cross-linked with CaCl2 solution as an external Ca
2+
source; self-hardening alginate [26] 5 % w/v cross-linked
with 34 mM glucono-δ-lactone (GDL), obtained from
Sigma-Aldrich (Missouri, USA), and 34 mM CaCO3
(Fluka, Switzerland); gelatin with a Bloom value of 300
(Gelita, Germany).
For the trials with rhBMP-2, alginate cross-linked with
CaCl2 was chosen as a carrier because of its ideal release
characteristics. The sodium alginate was produced as
5 % w/v alginate sol made with distilled water. To in-
crease rhBMP-2 solubility, we added hydrochloric acid
to pH 4. To ensure the best possible distribution in the
sol, rhBMP-2 (Pfizer) [50 μg/ml] or FITC-labeled Protein
A [50 μg/ml] were added to the distilled water immedi-
ately as production started. To prevent premature fad-
ing, the brine was homogenized in total darkness by
wrapping the beaker glass in aluminum foil. To load the
ceramics, we designed and manufactured a flow cham-
ber from stainless steel. A directional vacuum was used
for loading. There is a low vacuum of 40 mbar on one
side of the flow chamber, while the pressure is atmos-
pheric on the other side above the reservoir tank. In the
flow chamber, the ceramic dowels are inserted in a sili-
cone seal (FDA approved, LabMarket, Germany) that
ensures that loading occurs only via the end surfaces of
the microporous ceramic cylinders. This loading proced-
ure guarantees a 100 % load of the micropores [27].
After loading, the dowels were incubated in 30 mM
CaCl2 (Carl Roth, Germany) for 5 h at room
temperature (ca. 20 °C) to harden the gel.
Release kinetics
To simulate the physiological environment, the loaded
dowels (FITC-Prot.A n = 7; BMP-2 n = 6) were incubated
in phosphate buffer saline (gibco life technologies, Cali-
fornia) at 37 °C and 5 % CO2. The phosphate buffer sa-
line was completely replaced at each measuring point (1,
2, 3, 6, 9, 14, 21, 28 days).
The release of FITC-Protein A was measured via fluor-
escence spectroscopy (Tecan infinite 200) at 525 nm
wavelength, while absorption was 495 nm wavelength. A
six-point calibration curve was used (corr. R2 0,977).
The release of rhBMP-2 was measured by ELISA (R&D-
Systems, Minnesota, USA) according to the protocol
(seven-point Standard, corr. R2 0,988).
Osteoinductive capacity of released BMP-2
The efficacy of the released rhBMP-2 was calculated by
its effect on osteoblast-like cells (MG63, ATCC CRL-
1427). Those cells were grown in DMEM F12 Medium
(Lonza, Switzerland) and incubated in 5 % CO2 at 37 °C.
Live-dead assay
First, the toxic and apoptotic potential of the amount of
rhBMP-2 that had been released was assessed by
fluorescence-activated cell sorting (FACS) with propidium
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iodide(1 mg/ml, Invitrogen, California). FACS is a special-
ized type of flow cytometry. It enables the analysis of cells
that pass an electric voltage or a light beam at high speed.
Depending on the cells’ shape, structure, and/or staining,
different effects are produced from which the cells’ proper-
ties can be derived. Propidium iodide is discharged from
vital cells only. Propidium iodide-positive cells represent
dead or severely damaged cells.
1x104MG63 cells were seeded per well on 24-well-
plates and treated with 1 μg rhBMP-2 per 24 h for three
days, which was the maximum daily release. Afterwards
the cells were trypsinized, washed, and treated with 2 μl
propidium iodide solution. The populations were de-
tected by FACSCalibur flow cytometry (Becton Dickin-
son, New Jersey, USA). MG63-cells without rhBMP-2-
treatment served as a control. 1000 events were counted
per group.
To confirm our findings (3.3), we examined the cells
on the surface of the scaffold using a live/dead Cell
Staining Kit (Promokine, Germany). In this trial, 1x104
MG63 cells were seeded on top of the scaffold and dyed
with AM/EthD-III –dyeing after 24, 48 and 96 h.
Fluorescein dye has an excitation maximum at 495 nm
and an emission maximum at 515 nm (green). Ethidium
bromide is not absorbed by intact cell membranes, has
an excitation maximum at 530 nm and an emission
maximum at 635 nm (red). Vital cells reveal green, non-
vital cells red fluorescence in fluorescence microscopy
with blue light. The analysis was done manually.
Proliferation assay
Proliferation was measured with WST-1 Assay (Roche,
Switzerland). For each measuring point at 24 h, 48 h,
96 h ß-TCP dowels (n = 2) were loaded with 5 % w/v al-
ginate including 50 ng/ml rhBMP-2 and hardened with
30 mM CaCl2 as described above. The total amount of
rhBMP-2 was 3.85 μg per plug. Dowels loaded only with
5 % w/v alginate served as control. 1x10^4 MG63-cells
were seeded into 24-well-plates and incubated in 1 ml
DMEM F12 medium. After a settle-time of 8 h, the
loaded dowels were added to the medium and cells in
cell culture inserts (BDFalcon, New Jersey, USA) with a
pore size of 1 μm. At each measuring point the inserts
and dowels were removed, 100 μl of WST-1-reagent was
added and mixed well. After 2 h of incubation, absorption
was measured at 450 nm wavelength (Tecan infinite 200,
Tecan Group, Switzerland). Each sample was measured 4
times. The tetrazolium salts of the WST-1-reagent are
cleaved to formazan by cellular enzymes. An increase in
the number of viable cells raises the overall activity of
mitochondrial dehydrogenases and thereby an increase in
the total amount of formazan. This can be detected with a
Reader at a wavelength between 420-480 nm.
Alkaline phosphatase assay and confocal microscopy
Osteoblastic differentiation was meted with SensoLyte®
pNPP Alkaline Phosphatase Assay Kit (Anaspec EGT
Group, California, USA). For each measuring point at
3d, 7d, and 14d, ß-TCP dowels (n = 3) were loaded with
5 % w/v alginate including 50 ng/ml rhBMP-2 and hard-
ened with 30 mM CaCl2. The total amount of rhBMP-2
was 3.85 μg per dowel. Ceramics loaded only with
5 % w/v alginate served as a control. 1x104 MG63-cells
were seeded per well into 24-well-plates and incubated
in 1 ml DMEM F12 Medium (Lonza, Switzerland). After
8 h of settle-time, the loaded dowels were added to the
medium in cell culture inserts (BDFalcon, New Jersey,
USA) as described above. At the measuring points the
inserts and dowels were removed, the cells lysed with
Triton X-100, and the supernatant collected for the
assay. A seven-point calibration curve (corr. R2 0,998)
was set and each sample measured twice. The assay de-
tects only biologically-active alkaline phosphatase. p-
nitrophenyl phosphate is dephosphorylized by AP while
the substrate turns yellow and can be detected at
405 nm wavelength with a Reader.
Another way to demonstrate AP increase is via con-
focal microscopy (Leica TCS SP2 AOBS spectral con-
focal microscope), where light can be separated from the
object’s different levels. The use of fluorescent dyes and
the observation laser’s different wavelengths enable as-
sessment of the spatial distribution of labeled com-
pounds. In this case, 1x104 MG63-cells were seeded on
Thermanox® (Thermo Scientific, Massachusetts, USA)
membranes in 24-well-plates and incubated in 1 ml
DMEM F12 medium and treated with rhBMP-2, as re-
leased from the scaffolds for 5 days. After the treatment,
the cells were washed with phosphate buffer saline, fixed
with methanol, protein-blocked and incubated with pri-
mary antibody (rabbit anti-alkaline phosphatase 1:100,
Abcam, England) over night. The next day the mem-
branes were washed again and incubated with secondary
antibody (Donkey anti-Rabbit IgG, Alexa Fluor® 555; life
technologies, California) for 1 h. Cell nuclei were dyed
with DAPI (life-technologies, California).
Statistics
Data is expressed as mean values ± standard deviation of
the mean and analyzed by one-way analysis of variance
(ANOVA). The level of statistical significance was set as
p < 0.05. For statistical calculations Origin 9.1 Profes-
sional SR1 (OriginLab) was used.
Results
The most retardant hydrogel
FITC -Protein A release was very rapid from the gelatin
and self-hardening alginate: 80.9 % of the gelatin and
76.1 % from the self-hardening alginate had been
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released after 24 h. After 9 days, the concentration was
already under the detection limit.
The release of alginate with an external Ca2+ source
measured only 35.6 % of the total after 24 h. After the
release experiment, the scaffolds were broken and scruti-
nized under a fluorescence microscope. There was still
some FITC Protein A left in the scaffolds loaded with al-
ginate hardened with an external Ca2+ source, while
there was nothing in the dowels loaded with self-
hardening alginate and gelatin.
Thus the initial burst phase was significantly reduced
while the second release phase was prolonged for over
28 days (cf. Fig. 1). After 28 days of release, there is still
some FITC Protein A incorporated in micropores of the
scaffold loaded with alginate hardened with an external
Ca2+ source. In contrast to the self-hardening alginate,
the incorporated FITC Protein A can be visualized by
fluorescence microscopy (cf. Fig. 2a and b).
Retarded release of BMP-2 from an alginate-loaded ß-TCP
dowel
Release of rhBMP-2 from the ceramics was very similar.
Only the release on day 1 was lower, which can be ascribed
to rhBMP-2 or FITC-Prot. A missing in the hardening-
solution (CaCl2) and diffusion during the 5-h process.
Maximum release was 959 ± 222 ng/ml rhBMP-2 on the
second day. After 14, 21 and 28 days, we still observed a re-
lease of 268 ± 59 ng/ml, 111 ± 20 ng/ml and 56 ± 16 ng/ml.
There is thus an initial burst phase followed by lengthier
release phase lasting several weeks (cf. Fig. 3, raw data cf.
Additional File 1).
Fig. 1 Comparison of the release kinetics of three different
hydrogels regarding FITC Protein A measured by fluorescence reader
in a 28-day-trial (incubation at 37 °C, Phosphate buffer saline
changed completely at each measuring point): The alginate with
external Ca2+ source reveals a significantly reduced burst release,
while the second release phase is prolonged
Fig. 2 Fluorescence microscopy (Olympus BX-51, blue light filter) of
alginate and FITC-Protein A-loaded dowels after 28 days’ incubation
at 37 °C, Phosphate buffer saline changed completely at each
measuring point; a (left): Remaining FITC Protein A in dowel
(Alginate with external Ca2+ source) b (right): No FITC Protein A left
in dowel loaded with self-hardening alginate
Fig. 3 Considerably retarded release of BMP-2 from the externally-
hardened alginate-loaded ß-TCP dowel in a 28-day-trial; BMP-2 load
3.85 μg/scaffold; incubation at 37 °C; Phosphate buffer saline changed
completely at each measuring point
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Proliferation and osteogenic potential
The results of FACS measuring with propidium iodide
revealed no significant difference between the blanc and
the group treated with 1 μg/ml rhBMP-2 (Table 1).
Results of the live/dead assay with AM/EthD-III stain-
ing displayed no significant difference between the scaf-
folds with and without loading with rhBMP-2.
In the WST-1-Assay, the groups displayed significant
differences in proliferation rate at a significance level of
p < 0.05. Proliferation of the MG63 cells incubated with
the rhBMP-2 loaded scaffolds was significantly higher
at all measured time points (cf. Fig. 4, raw data cf.
Additional File 2). The increase was +38.3 % after 24 h,
rising to +50.3 % after 48 h and only +35.4 % when
reaching the culture plateau phase after 4 days.
The pNPP alkaline phosphatase assay revealed differences
between the blancs and rhBMP-2-group (cf. Fig. 5, raw data
cf. Additional File 3). The concentration of active AP in-
creased from 5.9 ± 0.9 ng/ml to 7.9 ± 0.3 ng/ml, equaling
24.8 % after 7 days. The increase after 14d was from 10.1 ±
1.3 ng/ml to 15.1 ± 2.8 ng/ml, or 33 %. These results were
not significant at a significance level of p < 0.05.
Discussion
Bone morphogenetic proteins have been investigated inten-
sively on both experimentally and clinically in orthopedic
surgery. Especially in the early stages of bone regeneration,
BMP-2 recruits local sources of skeletal progenitor cells
and determines their course towards the osteogenic lineage.
The current therapeutic application of BMP-2 for bone re-
pair is nevertheless associated with unacceptable side ef-
fects and very high doses. The ideal carrier matrix should
provide localized, retarded, and active BMP-2 delivery.
Moreover, it should fulfill cell, attachment, proliferation,
and differentiation requirements. We assumed that BMP-2
loaded microporous ß-TCP scaffolds, prepared by mixing
BMP-2 solution with alginate and by loading the porous
ceramics and hardening the alginate sol to a gel, would de-
liver a prolonged release system complying with these re-
quirements. With this method, it is possible to include any
concentration of one or more active ingredients in the scaf-
fold. After the alginate has been hardened with calcium
chloride, the diffusion from the gel -containing micropores
into the surrounding area is delayed. Significant delays are
observed in the release of antibiotics and growth factors
when applying this method [24]. The amount of delay can
be adjusted by altering the carrier substance's rheological
properties. Alginate and calcium concentrations can there-
fore be modified. Alternatively, an alginate with longer mo-
lecular chains could be used. However, microporous
ceramics cannot be loaded with fluids that are too viscous.
The Bernstein working group has explored the limits of this
loading process.
There are other means of controlling a substance’s re-
lease from bone-replacement materials. Zurlinden et al.
demonstrated that you can bind rhBMP-2 covalently to
calcium phosphate granular materials and delay the release
up to a few hundred days by using sodium acetate (half-life
up to 115 days) [28]. The amount of substances released
daily decreases with the prolongation of desorption. The
release period is longer than with hydrogels, but the
amount of substances released daily is lower [29].
Fig. 4 Significant proliferation differences in WST-1-Assay of MG63
cells after cultivation with BMP-2 and alginate-loaded ß-TCP scaffolds
for 24 h, 48 h and 96 h
Fig. 5 Expression of alkaline phosphatase in pNPP alkaline phosphatase
assay after cultivation with BMP-2 and alginate-loaded ß-TCP scaffolds
Table 1 MG63 cells after treatment with 1 μg BMP-2 per 24 h
for 3 days display no differences in survival, measured by FACS
with propidium Iodide
Group alive [%] dead [%]
Blanc 97.6 ± 0.4 2.4 ± 0.4
BMP-2 (1 μg/d) 97.8 ± 0.2 2.2 ± 0.2
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We have observed a burst release within the first 48 h
of release (45.4 %), while 50.9 % of the BMP-2 release
occurs during the remaining 28 days when a hydrogel is
combined with a ß-TCP ceramic. The relatively fast re-
lease of BMP-2 may be attributed to the relatively large
amount of BMP-2 adsorbed on hydrogel on the top of
ceramic cylinders due to the ceramic loading process. At
the last measuring point on day 28, 56 ± 16 ng/ml
remained: about 2 % of the BMP-2 measured. This con-
tinuous BMP-2 release implies that abundant BMP-2
had been packed into the ceramic micropores. We noted
homogeneous distribution of the hydrogel inside the en-
tire ceramic. This amount suffices to stimulate osteo-
blasts’ migration and differentiation. In-vitro effects of
BMPs are observed at very low doses (5-20 ng/mL) [16].
Most other studies have reported that substrate loaded
with BMP-2 has a significantly fast in-vitro release rate.
This has also revealed an initial burst release exceeding
50 %, and a slow slow-release stage [30, 31].
Many studies investigating BMP-2 delivery for bone re-
pair have applied relatively high doses ranging from tens to
hundreds of micrograms [32–34] and even 6-12 milligrams
[35]. This makes treatment costly while exacerbating the
drawback of side effects. High doses have also displayed
negative effects on different bone cells in-vitro, inducing
apoptosis from a few hundred nanograms upwards [36].
Our working group’s pretrials have yielded similar results.
Other recent studies have investigated the use of lower
doses in the range of a few micrograms [37] achieving for
example a 55 % increase in bone volume compared to
empty defects 6 weeks after the implantation of polymer
scaffolds containing only 1 μg BMP-2 in mice [38]. Find-
ings like these encouraged us to reduce the total BMP-2
load down to 3.85 μg per scaffold, enabling us to reduce
the daily release to significantly under the toxic and apop-
totic threshold while ensuring a maximum release of 1 μg/
day using the stiffest alginate from an external Ca2+ source
(in comparison to a self-hardening alginate). The combin-
ation of an alginate from an external Ca2+ source with
microporous ß-TCP ceramic provides a promising delivery
system for BMP-2. There would be enough BMP-2 in-vivo
in the first 4 weeks of bone healing, with just a little left
for the remainder of the degradation period (52 weeks in a
sheep model [11]). The other hydrogels we investigated
(self-hardening alginate and gelatin) displayed a significant
burst release due to their greater physical solubility. They
are therefore unsuitable in a carrier system. Apart from
the fact that the release of rhBMP-2 and Protein A is very
similar, it is a good and inexpensive model substance.
BMP-2's in-vivo effects on osteoblasts and bone are well
known [39]. Our trial was designed to demonstrate that
released rhBMP-2 remains active after being dissolved in
alginate following the loading procedure and release. We
hypothesized that proliferation and the expression of
osteogenic markers like AP would rise, as described in
other studies [40].
BMP-2 proliferation seems to have contradictory ef-
fects on different types of cells. Fromigue’ et. al. postu-
lated in 1998 that BMP-2 decreases proliferation up to
35 % in human bone marrow cells representing early
progenitors [41] while other groups were unable to de-
tect significant differences in osteosarcoma cell lines
representing osteoblast-like-cells [42]. Having observed
no other differences between the groups, we attribute
this increase in proliferation to the released BMP-2.
Fig. 6 A (BMP-2) and 6 B (blanc): Confocal microscopy of MG63 cells
after treatment with rhBMP-2 (left) and without (right) for 5 days,
differences in expression of alkaline phosphatase. Cell nuclei blue
(DAPI), AP red (rabbit anti-AP-AB; donkey anti rabbit, Alexa555)
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The rhBMP-2 treated groups displayed higher AP ac-
tivity than the groups lacking rhBMP-2 (cf. Fig. 6) (up to
33 % in our experiments), but not to a significant degree
in the alkaline phosphatase assay. Perhaps the measuring
points play a role; Draenert et. al. describe the maximum
difference at 24 h using human osteoblasts [40]. Higher
case numbers could also have helped achieve more con-
vincing findings, as other working groups have employed
[43]. Furthermore, rhBMP-2 handling could be opti-
mized. A combination with heparin may lead to further
improvement because heparin is a highly sulfated glycos-
aminoglycan known to bind to BMP-2 and stimulate its
activity by protecting it from enzymatic degradation and
the antagonistic actions of noggin [44], a protein in-
volved in the development of tissues such as nerves,
muscles, and especially bones. The same working group
showed that acidic pH and the use of glass vials can lead
to improved BMP-2 stability when compared with
physiological pH and the use of plastic vials [45].
Conclusion
It was our aim to amalgamate an osteoconductive, micro-
porous, interconnective ß-TCP-scaffold with rhBMP-2.
This scaffold consisting of a microporous ß-TCP ceramic
and an alginate hydrogel with rhBMP-2 represents a
promising delivery system for BMP-2.
We observed that BMP-2 exerts effects on osteoblast-
like cells at very low doses over a lengthy period. We
also believe that such scaffolds can lead to better and
safer outcomes in humans.
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